• Adamczyk, M., Gebler, J., Shreder, K., and Wu, J. 2000. Region-selective labeling of antibodies as determined by electrospray ionization-mass spectrometry (ESI-MS). Bioconjug. Chem. 11: 557563.
  • Blättler, W.A. and Chari, R.V.J. 2001. Drugs to enhance the therapeutic potency of anti-cancer antibodies: Antibody-drug conjugates as tumor-activated prodrugs. In Anticancer agents: Frontiers in cancer chemotherapy (eds. OjimaI. et al.), pp. 317338. American Chemical Society, Washington, DC.
  • Bongers, J., Cummings, J.J., Ebert, M.B., Federici, M.M., Gledhill, L., Gulati, D., Hilliard, G.M., Jones, B.H., Lee, K.R., Mozdzanowski, J., et al. 2000. Validation of a peptide mapping method for a therapeutic monoclonal antibody: What could we possibly learn about a method we have run 100 times? J. Pharm. Biomed. Anal. 21: 10991128.
  • Cassady, J.M., Chan, K.K., Floss, H.G., and Leistner, E. 2004. Recent developments in the maytansinoid antitumor agents. Chem. Pharm. Bull. (Tokyo) 52: 126.
  • Feng, R. and Konishi, Y. 1992. Analysis of antibodies and other large glycoproteins in the mass range of 150,000–200,000 Da by electrospray ionization mass spectrometry. Anal. Chem. 64: 20902095.
  • Fossella, F.V., Tolcher, A., Elliott, M., Lambert, J.M., Lu, R., Zinner, R., Lu, C., Oh, Y., Forouzesh, B., McCreary, H., et al. 2002. Phase I trial of the monoclonal antibody conjugate, BB-10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. In American Society of Clinical Oncology Annual Meeting, Orlando, FL.
  • Grillo-Lopez, A.J., Dallaire, B.K., McClure, A., Weaver, R., Varns, C., Wei, A., Allen, R., Lee, D., Shen, D., Leonard, J., et al. 2001. Monoclonal antibodies: A new era in the treatment of non-Hodgkin's lymphoma. Curr. Pharm. Biotechnol. 2: 301311.
  • Kim, J.A. 2003. Targeted therapies for the treatment of cancer. Am. J. Surg. 186: 264268.
  • Krapp, S., Mimura, Y., Jefferis, R., Huber, R., and Sondermann, P. 2003. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325: 979989.
  • Lazar, A.C., Wang, L., Blättler, W.A., Amphlett, G., Lambert, J.M., and Zhang, W. 2005. Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun. Mass Spectrom. 19: 18061814.
  • Leavell, M.D., Novak, P., Behrens, C.R., Schoeniger, J.S., and Kruppa, G.H. 2004. Strategy for selective chemical cross-linking of tyrosine and lysine residues. J. Am. Soc. Mass Spectrom. 15: 16041611.
  • Lewis, D.A., Guzzetta, A.W., Hancock, W.S., and Costello, M. 1994. Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC/MS, and MS/MS. Anal. Chem. 66: 585595.
  • Liu, C., Tadayoni, B.M., Bourret, L.A., Mattocks, K.M., Derr, S.M., Widdison, W.C., Kedersha, N.L., Ariniello, P.D., Goldmacher, V.S., Lambert, J.M., et al. 1996. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. 93: 86188623.
  • Lo-Coco, F., Cimino, G., Breccia, M., Noguera, N.I., Diverio, D., Finolezzi, E., Pogliani, E.M., Di Bona, E., Micalizzi, C., Kropp, M., et al. 2004. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104: 19951999.
  • Lu, S.X., Takach, E.J., Solomon, M., Zhu, Q., Law, S.J., and Hsieh, F.Y. 2005. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. J. Pharm. Sci. 94: 788797.
  • Milenic, D.E. 2002. Monoclonal antibody-based therapy strategies: Providing options for the cancer patient. Curr. Pharm. Des. 8: 17491764.
  • Pintar, A., Carugo, O., and Pongor, S. 2003. DPX: For the analysis of the protein core. Bioinformatics 19: 313314.
  • Rodriguez, R., Chinea, G., Lopez, N., Pons, T., and Vriend, G. 1998. Homology modeling, model and software evaluation: Three related resources. CABIOS 14: 523528.
  • Roguska, M.A., Pedersen, J.T., Keddy, C.A., Henry, A.H., Searle, S.J., Lambert, J.M., Goldmacher, V.S., Blättler, W.A., Rees, A.R., and Guild, B.C. 1994. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. 91: 969973.
  • Ross, J., Gray, K., Schenkein, D., Greene, B., Gray, G.S., Shulok, J., Worland, P.J., Celniker, A., and Rolfe, M. 2003. Antibody-based therapeutics in oncology. Expert Rev. Anticancer Ther. 3: 107121.
  • Sheriff, S., Chang, C.Y., Jeffrey, P.D., and Bajorath, J. 1996. X-ray structure of the uncomplexed anti-tumor antibody BR96 and comparison with its antigen-bound form. J. Mol. Biol. 259: 938946.
  • Siegel, M. M., Tabei, K., Kunz, A., Hollander, I.J., Hamann, R.R., Bell, D.H., Berkenkamp, S., and Hillenkamp, F. 1997. Calicheamicin derivatives conjugated to monoclonal antibodies: Determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ ionization mass spectrometry and electrospray ionization mass spectrometry. Anal. Chem. 69: 27162726.
  • Tassone, P., Gozzini, A., Goldmacher, V., Shammas, M.A., Whiteman, K.R., Carrasco, D.R., Li, C., Allam, C.K., Venuta, S., Anderson, K.C., et al. 2004. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 64: 46294636.
  • Wang, L., Amphlett, G., Lambert, J.M., Blättler, W.A., and Zhang, W. 2005. Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry. Pharm. Res. (in press).
  • Zeromski, J., Nyczak, E., and Dyszkiewicz, W. 2001. Significance of cell adhesion molecules, CD56/NCAM in particular, in human tumor growth and spreading. Folia Histochem. Cytobiol. 39 (Suppl. 2): 3637.